✦ LIBER ✦

6620 Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in the treatment of advanced hepatocellular carcinoma (HCC)

✍ Scribed by Pastorelli, D.; Zustovich, F.; Lombardi, G.; Zovato, S.; Farina, M.; Furini, L.; Faggioni, G.; Nicoletto, M.O.; Ceravolo, R.

Book ID: 122477311
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 68 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71341-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pegylated liposomal doxorubicin and gemc

Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma : Results of a phase 2 study

✍ Giuseppe Lombardi; Fable Zustovich; Fabio Farinati; Umberto Cillo; Alessandro Vi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 2 views

A phase II and pharmacokinetic study of

A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma

✍ Ruey-Long Hong; Yun-Long Tseng 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 200 KB

Single-agent pegylated liposomal doxorub

Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

✍ Michael Fiegl; Brigitte Mlineritsch; Michael Hubalek; Rupert Bartsch; Ursula Plu 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 191 KB

Pegylated liposomal doxorubicin and gemc

Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study

✍ Adamo, V; Lorusso, V; Rossello, R; Adamo, B; Ferraro, G; Lorusso, D; Condemi, G; 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 126 KB

Comparison of doxorubicin and tamoxifen

Comparison of doxorubicin and tamoxifen vs. tamoxifen in the treatment of advanced hepatocellular carcinoma

✍ Schachschal, G.; Lochs, H.; Plauth, M. 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 141 KB

326 POSTER Dose-finding study of pegylat

326 POSTER Dose-finding study of pegylated liposomal doxorubicin (PLD) and the mTOR inhibitor RAD001 (R) in patients (pts) with advanced solid tumors

✍ C. Sessa; A. Perotti; A. Delmonte; G. Del Conte; E. Gallerani; A. Fasolo; F. Zan 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB